Previously recorded as Tissuetech, Inc. (to 2023)
25 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in May 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
May 2027
Next term end
16
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2028 · High confidence
Also notable
Ends May 2027 · High confidence
Also notable
Ends Dec 2028 · High confidence
Also notable
Ends Jul 2033 · High confidence
Also notable
Ends Jun 2033 · High confidence
Also notable
Ends no later than Jun 2035 · Medium confidence
Also notable
Ends Apr 2037 · High confidence
Also notable
Ends Aug 2032 · High confidence
Amniotic Membrane Preparations and Purified Compositions and Therapy for Scar Reversal and Inhibition
US 8,182,840
Cited by 111 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Purified Amniotic Membrane Compositions and Methods of Use
US 8,153,162
The most cited patent in this portfolio, cited by 196 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2027.
Amniotic Membrane Preparations and Purified Compositions and Anti-Inflammation Methods
US 8,182,841
Cited by 115 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Compositions Containing HC-HA/PTX3 Complexes and Methods of Use Thereof
US 10,040,821
Cited by 16 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Methods of Processing Fetal Support Tissues, Fetal Support Tissue Powder Products, and Uses Thereof
US 9,682,044
Cited by 29 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Compositions of Morselized Umbilical Cord And/Or Amniotic Membrane and Methods of Use Thereof
US 9,808,491
Cited by 24 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Compositions and Methods for Preventing the Proliferation and Epithelial-Mesenchymal Transition of Epithelial Cells
US 10,342,831
Cited by 10 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2037.
Methods of Sterilizing Fetal Support Tissues
US 9,682,160
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2032.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 9 to 25, 2027 · next Jan 9
- 1 fee due Mar 8, 2027The maintenance fee for Cell-Free Graft (US 9,125,871) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
- 1 fee due Apr 1, 2027The maintenance fee for Methods of Processing Fetal Support Tissues, Fetal Support Tissue Powder Products, and Uses Thereof (US 10,426,731) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- 13 terms have ended since Aug 23, 2026
- Sep 27 US 9,956,252 Purified Amniotic Membrane Compositions and Methods of Use · term ended
- Sep 27 US 9,750,772 Amniotic Membrane Preparations and Purified Compositions and Anti-Angiogenesis Treatment · term ended
- Sep 27 US 9,750,771 Amniotic Membrane Preparations and Purified Compositions and Anti-Inflammation Methods · term ended
- Sep 27 US 9,724,370 Amniotic Membrane Preparations and Purified Compositions and Therapy for Scar Reversal and Inhibition · term ended
- Sep 27 US 9,198,939 Purified Amniotic Membrane Compositions and Methods of Use · term ended
- Sep 27 US 9,161,956 Amniotic Membrane Preparations and Purified Compositions and Anti-Inflammation Methods · term ended
- Sep 27 US 9,161,955 Amniotic Membrane Preparations and Purified Compositions and Therapy for Scar Reversal and Inhibition · term ended
- Sep 27 US 9,161,954 Amniotic Membrane Preparations and Purified Compositions and Anti-Angiogenesis Treatment · term ended
- Sep 27 US 8,460,714 Purified Amniotic Membrane Compositions and Methods of Use · term ended
- Sep 27 US 8,455,009 Amniotic Membrane Preparations and Purified Compositions and Anti-Inflammation Methods · term ended
- Sep 27 US 8,440,235 Amniotic Membrane Preparations and Purified Compositions and Therapy for Scar Reversal and Inhibition · term ended
- Sep 27 US 8,420,126 Amniotic Membrane Preparations and Purified Compositions and Anti-Angiogenesis Treatment · term ended
- Sep 27 US 10,272,119 Amniotic Membrane Preparations and Purified Compositions and Therapy for Scar Reversal and Inhibition · term ended
What they patent
The largest of its 16 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,153,162 | Purified Amniotic Membrane Compositions and Methods of Use In force · High confidence | In force | High confidence | |
| US 9,006,192 | RNAi Methods and Compositions for Stimulating Proliferation of Cells with Adherent Junctions In force · High confidence | In force | High confidence | |
| US 8,182,841 | Amniotic Membrane Preparations and Purified Compositions and Anti-Inflammation Methods In force · High confidence | In force | High confidence | |
| US 8,182,840 | Amniotic Membrane Preparations and Purified Compositions and Therapy for Scar Reversal and Inhibition In force · High confidence | In force | High confidence | |
| US 9,125,871 | Cell-Free Graft held by Biotissue AG In force · Medium confidence | In force | Medium confidence | |
| US 12,397,086 | Methods of Modulating Bone Remodeling In force · High confidence | In force | High confidence | |
| US 10,426,731 | Methods of Processing Fetal Support Tissues, Fetal Support Tissue Powder Products, and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,682,160 | Methods of Sterilizing Fetal Support Tissues In force · High confidence | In force | High confidence | |
| US 8,940,294 | Methods of Isolating and Culturing Stem Cells In force · High confidence | In force | High confidence | |
| US 9,682,044 | Methods of Processing Fetal Support Tissues, Fetal Support Tissue Powder Products, and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 25: 4 patents in force now held by others · 21 patents ended · 11 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.